
Sign up to save your podcasts
Or
This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.
4.8
168168 ratings
This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.
325 Listeners
493 Listeners
58 Listeners
280 Listeners
3,332 Listeners
1,095 Listeners
192 Listeners
43 Listeners
519 Listeners
349 Listeners
248 Listeners
109 Listeners
56 Listeners
366 Listeners
39 Listeners